These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1515646)

  • 21. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
    Snyder DS; Wu Y; Wang JL; Rossi JJ; Swiderski P; Kaplan BE; Forman SJ
    Blood; 1993 Jul; 82(2):600-5. PubMed ID: 8329715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 19-Allylaminoherbimycin A, an analog of herbimycin A that is stable against treatment with thiol compounds or granulocyte-macrophage colony-stimulating factor in human leukemia cells.
    Makishima M; Yamamoto-Yamaguchi Y; Honma Y
    Biochim Biophys Acta; 1995 Dec; 1272(3):199-205. PubMed ID: 8541353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism.
    Fukazawa H; Uehara Y; Murakami Y; Mizuno S; Hamada M; Takeuchi T
    FEBS Lett; 1994 Mar; 340(3):155-8. PubMed ID: 8131836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
    Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
    Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
    Schwartz GN; Liu YQ; Tisdale J; Walshe K; Fowler D; Gress R; Bergan RC
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):329-39. PubMed ID: 9743470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
    Honma Y; Kasukabe T; Hozumi M; Shibata K; Omura S
    Anticancer Res; 1992; 12(1):189-92. PubMed ID: 1567167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
    Svingen PA; Tefferi A; Kottke TJ; Kaur G; Narayanan VL; Sausville EA; Kaufmann SH
    Clin Cancer Res; 2000 Jan; 6(1):237-49. PubMed ID: 10656455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds.
    Uehara Y; Fukazawa H; Murakami Y; Mizuno S
    Biochem Biophys Res Commun; 1989 Sep; 163(2):803-9. PubMed ID: 2783121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.
    Hallek M; Danhauser-Riedl S; Herbst R; Warmuth M; Winkler A; Kolb HJ; Druker B; Griffin JD; Emmerich B; Ullrich A
    Br J Haematol; 1996 Jul; 94(1):5-16. PubMed ID: 8757502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blast crisis in a murine model of chronic myelogenous leukemia.
    Daley GQ; Van Etten RA; Baltimore D
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11335-8. PubMed ID: 1763047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.